eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) As of 02:13 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. NMTR, AMPE, PXMD, CALA, HSTO, ONCSQ, ATNFW, LBPSW, AEHAW, and AIMDWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include 9 Meters Biopharma (NMTR), Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), Calithera Biosciences (CALA), Histogen (HSTO), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), and Ainos (AIMDW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors 9 Meters Biopharma Ampio Pharmaceuticals PaxMedica Calithera Biosciences Histogen OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos eFFECTOR Therapeutics (NASDAQ:EFTR) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Which has stronger earnings & valuation, EFTR or NMTR? 9 Meters Biopharma is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.009 Meters BiopharmaN/AN/A-$43.77M-$3.460.00 Which has more risk & volatility, EFTR or NMTR? eFFECTOR Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Do institutionals & insiders have more ownership in EFTR or NMTR? 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to EFTR or NMTR? In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment eFFECTOR Therapeutics Neutral 9 Meters Biopharma Neutral Is EFTR or NMTR more profitable? eFFECTOR Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets eFFECTOR TherapeuticsN/A N/A N/A 9 Meters Biopharma N/A -584.97%-159.45% SummaryeFFECTOR Therapeutics beats 9 Meters Biopharma on 6 of the 8 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$792.54M$5.45B$9.68BDividend YieldN/A4.84%3.99%4.14%P/E Ratio0.001.3130.0525.00Price / SalesN/A25.14378.2478.85Price / CashN/A19.5635.9458.58Price / Book0.006.558.145.68Net Income-$35.81M-$4.07M$3.25B$265.58M7 Day PerformanceN/A0.30%1.16%2.51%1 Month PerformanceN/A5.04%2.82%1.88%1 Year PerformanceN/A24.76%28.41%24.02% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR Therapeutics0.0857 of 5 stars$0.00flatN/A-99.6%$1KN/A0.0010High Trading VolumeNMTR9 Meters BiopharmaN/A$0.00+∞N/AN/A$3KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+31.8%$3KN/A0.0020PXMDPaxMedicaN/A$0.00+100.0%N/A-99.9%$2KN/A0.002Gap UpCALACalithera Biosciences2.0709 of 5 stars$0.00-66.7%N/A-95.6%$1KN/A0.0060HSTOHistogenN/A$0.00flatN/AN/A$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040ATNFW180 Life SciencesN/A$0.01-0.9%N/A-7.4%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01+84.9%N/A-75.6%$0.00N/A0.002Gap DownAIMDWAinosN/A$0.11-8.3%N/AN/A$0.00$106.21K0.0040Gap Up Related Companies and Tools Related Companies 9 Meters Biopharma Alternatives Ampio Pharmaceuticals Alternatives PaxMedica Alternatives Calithera Biosciences Alternatives Histogen Alternatives OncoSec Medical Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts